WO2003030887A1 - Composition and method for improving sexual desire and erectile function - Google Patents

Composition and method for improving sexual desire and erectile function Download PDF

Info

Publication number
WO2003030887A1
WO2003030887A1 PCT/US2001/031447 US0131447W WO03030887A1 WO 2003030887 A1 WO2003030887 A1 WO 2003030887A1 US 0131447 W US0131447 W US 0131447W WO 03030887 A1 WO03030887 A1 WO 03030887A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
aspartate
androstenediol
lycopene
lecithin
Prior art date
Application number
PCT/US2001/031447
Other languages
French (fr)
Inventor
Don Perry Haygood
Original Assignee
Herturn, L.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Herturn, L.L.C. filed Critical Herturn, L.L.C.
Priority to PCT/US2001/031447 priority Critical patent/WO2003030887A1/en
Publication of WO2003030887A1 publication Critical patent/WO2003030887A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A61K36/296—Epimedium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto

Definitions

  • This invention relates generally to sexual enhancers. More specifically, this invention relates to a composition and method for improving sexual desire and erectile function.
  • ED Male erectile dysfunction
  • impotence is the inability for a sexually active male to obtain and sustain an erection for sexual purposes. Symptoms may also include loss of sexual desire, premature ejaculation, or inability to achieve orgasm. About 30 million men in the United States alone suffer from some degree of ED.
  • Erectile dysfunction can have physical, psychological or drug-induced causes. Most researchers and doctors now believe that physical factors are responsible for the majority of erectile dysfunction cases. Erections are caused by an increase in blood flow into the small arteries of the penis. Dilation of blood vessels necessary for a normal erection depends on a substance called nitric oxide, and nitric oxide formation depends on the amino acid arginine. Impotence can be a sign of a more serious health condition. Restriction of blood flow is the actual cause of impotence. Several health conditions cause this restriction of blood flow throughout the body. Cardiovascular conditions and poorly controlled diabetes can cause circulatory problems that may lead to erectile problems. Hormonal imbalances may also cause erectile dysfunction.
  • ED vascular disease and diabetes.
  • the majority of men with ED suffer from these and other physical causes, including hormone disorders, high blood pressure, spinal cord injuries, multiple sclerosis, prostate or pelvic surgery, heart problems, venous leaks from the penis, certain medication use and substance/alcohol abuse.
  • Smoking doubles the probability of ED when combined with another risk factor, and is itself a cause of blood flow problems.
  • ED has a psychological foundation such as depression or anxiety. Sometimes ED is simply a manifestation of a relationship problem.
  • Sexual potency is related to feelings of power, competence, self-confidence and a healthy sense of narcissim.
  • sexual potency begins to wane, the man may feel that he is losing control of himself, of his mind, his body, and of being able to influence his world. These feelings can lead to anxiety, depression and an inability to function in the world from an interpersonal, business and professional level. When this happens, the man and usually the people in his life suffer.
  • conventional therapy may include psychological and behavioral counseling, treatment of underlying cardiovascular disease and avoidance of certain medications (such as cimetidine, antihypertensives and MAO inhibitors).
  • Drug treatments for ED include male hormone replacement therapy (testoterone,
  • impotency treatment only works in approximately 82% of men who use it. Moreover, as it is a prescription medication, an office visit to a health care provider is required
  • VIAGRA® is
  • VIAGRA® is only recommended to be taken
  • VIAGRA® begins
  • Penile vacuum devices and surgical procedures such as penile implants and vascular repair, are usually limited to those who have not responded to other treatments. None the current options have been entirely successful in improving sexual desire or erectile function.
  • the present invention relates to a natural composition and method of improving sexual desire and erectile function by oral administration of a dietary supplement composition comprising about: 40-65 mg Androstenedione
  • Vitamin B-6 (pyridoxide HCL 82%) 0-50 mg Lycopene 1%
  • the composition comprises about:
  • the method of the invention comprises administering the composition orally two times per day on a routine daily regimen.
  • the present invention is concerned with a composition and method for improving sexual desire and erectile function and overall sexual vitatlily.
  • the composition comprises in each dose in a 00 gel capsule, generally about:
  • Vitamin B-6 (pyridoxide HCL 82%)
  • composition in each capsule comprises about:
  • composition is manufactured according to good manufacturing practices (GMPs) recommended by the National Nutritional Foods Association.
  • GMPs good manufacturing practices
  • the following batch weights are provided:
  • Each raw material component is subjected to an identity test (typically thin layer chromatography) and scaled up individually and upon completion of that task, all materials are transferred to a planetary blender (capacity approximately 500 Kilograms) to blend all components. The blending process lasts for approximately 1 hour at room temperature at which time the ingredients are removed and taken to an encapsulation room for encapsulation.
  • the raw materials are available from such suppliers as Sabinsa Corp., 121
  • the composition is administered orally, preferable in gelatin capsules.
  • the suggested dose schedule is one capsule two times per day, morning and evening, or as directed by a health care professional.
  • the composition may of course be incorporated in other delivery methods, such as tablets, etc. by methods known to persons skilled in the art.
  • the composition may be
  • VIAGRA® administered with VIAGRA® if permitted by a health care professional.
  • composition and method is effective in improving sexual desire and erectile function to increase sexual vitality and the male's sense of well-being and to improve sexual performance.
  • the use of the composition may be substantially less expensive, less intrusive, and less toxic than some of the currently available treatments.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A composition and method for improving sexual desire and erectile function is disclosed in which a sufferer is administered orally a natural composition containing Androstenedione, 4-Androstenediol, Zinc monomethionine, Magnesium aspartate, B-6, lycopene, lecithin, serenoa repens and epimedium sagittatum in an effective amoutn.

Description

COMPOSITION AND METHOD FOR IMPROVING SEXUAL DESIRE AND
ERECTILE FUNCTION
FIELD OF THE INVENTION
This invention relates generally to sexual enhancers. More specifically, this invention relates to a composition and method for improving sexual desire and erectile function.
BACKGROUND OF THE INVENTION
Male erectile dysfunction (ED) (also called impotence) is the inability for a sexually active male to obtain and sustain an erection for sexual purposes. Symptoms may also include loss of sexual desire, premature ejaculation, or inability to achieve orgasm. About 30 million men in the United States alone suffer from some degree of ED.
Erectile dysfunction can have physical, psychological or drug-induced causes. Most researchers and doctors now believe that physical factors are responsible for the majority of erectile dysfunction cases. Erections are caused by an increase in blood flow into the small arteries of the penis. Dilation of blood vessels necessary for a normal erection depends on a substance called nitric oxide, and nitric oxide formation depends on the amino acid arginine. Impotence can be a sign of a more serious health condition. Restriction of blood flow is the actual cause of impotence. Several health conditions cause this restriction of blood flow throughout the body. Cardiovascular conditions and poorly controlled diabetes can cause circulatory problems that may lead to erectile problems. Hormonal imbalances may also cause erectile dysfunction. The two most single causes of ED are vascular disease and diabetes. The majority of men with ED suffer from these and other physical causes, including hormone disorders, high blood pressure, spinal cord injuries, multiple sclerosis, prostate or pelvic surgery, heart problems, venous leaks from the penis, certain medication use and substance/alcohol abuse. Smoking doubles the probability of ED when combined with another risk factor, and is itself a cause of blood flow problems. In some cases, ED has a psychological foundation such as depression or anxiety. Sometimes ED is simply a manifestation of a relationship problem.
Men can also experience low libido, or sex drive, with or without erectile problems. This loss of sexual drive may be related to "male menopause", illness, stress, depression, excessive use of drugs and/or alcohol, and certain prescription medications. What defines a low libido for an individual is subjective and depends upon many variables. Physical and mental health are key factors and sex drive may decrease with age. While any illness can decrease sex drive, some conditions, such as thyroid disease, tumors of the pituitary gland (which controls most hormone production, including sex hormones), and depression, are directly linked to low libido. Similarly insufficient amounts of the male sex hormone testosterone may cause low libido, though such a condition is unlikely to affect erectile function. Drugs and stress can also decrease libido.
Sexual potency is related to feelings of power, competence, self-confidence and a healthy sense of narcissim. When sexual potency begins to wane, the man may feel that he is losing control of himself, of his mind, his body, and of being able to influence his world. These feelings can lead to anxiety, depression and an inability to function in the world from an interpersonal, business and professional level. When this happens, the man and usually the people in his life suffer. Depending on the cause, conventional therapy may include psychological and behavioral counseling, treatment of underlying cardiovascular disease and avoidance of certain medications (such as cimetidine, antihypertensives and MAO inhibitors). Drug treatments for ED include male hormone replacement therapy (testoterone,
DHEA), sildenafil citrate (VIAGRA®), and medications inserted or injected into the
penis (alprostadil). The herbs yohimbe and yohimbine (the primary active constituent
in yohimbe) have also been found to be helpful. Viagra®, the most well-known
impotency treatment only works in approximately 82% of men who use it. Moreover, as it is a prescription medication, an office visit to a health care provider is required
increasing the costs and embarrassing some ED sufferers. Moreover, VIAGRA® is
not recommended for men on nitrate medication for heart disease or suffering from the rare eye disease retinitis pigmentosa. As with all drugs, side effects may occur and the cost of these drugs is significant, especially when one considers the added cost of
the required office visit. Moreover, VIAGRA® is only recommended to be taken
once a day about one hour before engaging in sexual activity thus effectively limiting
sexual activity to once per day. For most patients, the effect of VIAGRA® begins
about 30 minutes after it is taken and lasts up to four hours. Penile vacuum devices and surgical procedures, such as penile implants and vascular repair, are usually limited to those who have not responded to other treatments. None the current options have been entirely successful in improving sexual desire or erectile function.
Accordingly, there has been a need for another weapon in the armamentarium against ED and against no or low sexual desire. There is an additional need for a composition and method to achieve optimum or ultimate sexual vitality. There also exists a need for a composition and method of improving sexual desire and erectile function that are natural, convenient, non-toxic, and can be obtained without embarrassment, a prescription, or the cost of an office visit. There has also been a need for a novel composition and method that are safe and effective to use on a routine basis rather than just prior to or during sexual activity. There is a still further need for a composition and method that are less intrusive and permitting more spontaneity than conventional therapies with the possibility of repeated sexual activity not limited to once per day as with some conventional therapies. There is an additional need for a composition and method that may be used in addition to conventional therapies to improve sexual vitality overall. The present invention fulfills these needs and provides other related advantages.
SUMMARY OF THE INVENTION The present invention relates to a natural composition and method of improving sexual desire and erectile function by oral administration of a dietary supplement composition comprising about: 40-65 mg Androstenedione
20-45 mg 4-Androstenediol
15 mg or less Zinc Monomethionine Aspartate
80-125 mg Magnesium Aspartate
20-45 mg Vitamin B-6 (pyridoxide HCL 82%) 0-50 mg Lycopene 1%
60-125 mg Lecithin
75-150 mg Serenoa Repens
75-200 mg Epimedium Sagittatum In a preferred form of the invention, the composition comprises about:
50 mg Androstenedione 25 mg 4-Androstenediol 15 mg Zinc Monomethionine Aspartate 100 mg Magnesium Aspartate 5 mg B-6 (pyrodoxide Hcl) 15 mg Lycopene 100 mg Lecithin 100 mg Serenoa Repens
100 mg Epimedium Sagittatum
The method of the invention comprises administering the composition orally two times per day on a routine daily regimen.
Other features and advantages of the present invention will become apparent from the following more detailed description.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
The present invention is concerned with a composition and method for improving sexual desire and erectile function and overall sexual vitatlily. The composition comprises in each dose in a 00 gel capsule, generally about:
40-65 mg Androstenedione 20-45 mg 4 Androstenediol
15 mg or less Zinc Monomethionine Aspartate
80-125 mg Magnesium Aspartate
20-45 mg Vitamin B-6 (pyridoxide HCL 82%)
0-50 mg Lycopene 1% 60-125 mg Lecithin
80-150 mg Serenoa Repens
75-200 mg Epimedium Sagittatum (horny Goat Weed)
In a preferred form of the invention, the composition in each capsule comprises about:
50 mg Androstenedione 100% Pharmaceutical Grade
25 mg 4-Androstenediol 100% Pharmaceutical Grade
15 mg Zinc Monomethionine 15 mg Elemental Zinc
100 mg Magnesium Aspartate 20% Elemental Magnesium 25 mg B-6 (pyrodoxide HCL) 82% material
15 mg Lycopene 1% material
100 mg Lecithin 100% material
100 mg Serenoa Repens Standardized to 85%-95% fatty acids and stearols 100 mg Epimedium Sagittatum Standardized 10% Icariin These amounts substantially ensure maximum effect. Through investigation and research, the particular range of components, and in particular these optimal amounts within the ranges, have been found to substantially improve sexual desire and erectile function. Fillers such as maltodextrin, magnesium stearate, and other known flow agents may be added to substantially prevent the composition from clumping.
The composition is manufactured according to good manufacturing practices (GMPs) recommended by the National Nutritional Foods Association. In order to make 'OO" capsules each containing the preferred form of the invention, the following batch weights are provided:
270.000 Capsules 540.000 Capsules
Androstenedione 13.5 Kg (6.1236 Lbs) 27Kg (12.2472 Lbs.)
4-Androstenediol 6.75Kg (3.0618 Lbs.) 13.5Kg (6.1236
Lbs.)
Zinc Monomethionine Aspartate 4.05Kg (1.837 Lbs.) 8.1Kg (3.674
Lbs.) Magnesium Aspartate 27Kg (12.25 Lbs.) 54Kg (24.5 Lbs.)
B-6 (pyridoxide HC1) 6.75Kg (3.0618 Lbs.) 13.5Kg (6.1236
Lbs.)
Lycopene 4.05Kg (1.837 Lbs.) 8.1Kg (3.674
Lbs.) Lecithin 27Kg (12.25 Lbs.) 54Kg (24.5 Lbs.)
Serenoa Repens 27Kg (12.25 Lbs.) 54Kg (24.5 Lbs.)
Epimedium Sagittatum . 27Kg (12.25 Lbs) 54Kg (24.5 Lbs.)
Total Weight For Batch of 270,000 Capsules - 143. IK (64.9212 Lbs.) Total Weight For Batch of 540,000 Capsules - 286.2K (129.8424 Lbs).
Each raw material component is subjected to an identity test (typically thin layer chromatography) and scaled up individually and upon completion of that task, all materials are transferred to a planetary blender (capacity approximately 500 Kilograms) to blend all components. The blending process lasts for approximately 1 hour at room temperature at which time the ingredients are removed and taken to an encapsulation room for encapsulation. The raw materials are available from such suppliers as Sabinsa Corp., 121
Ethel Road West, Unit 6, Piscataway, N.J. 08854, Seltzer Chemicals, 5927 Geiger Court, Carlsbad, CA 92008, and AIDP Inc., 1120 Coiner Court, City of Industry, CA 91748.
In the method of the invention, the composition is administered orally, preferable in gelatin capsules. The suggested dose schedule is one capsule two times per day, morning and evening, or as directed by a health care professional. The composition may of course be incorporated in other delivery methods, such as tablets, etc. by methods known to persons skilled in the art. The composition may be
administered with VIAGRA® if permitted by a health care professional.
Preliminary studies on the toxicity of the composition on rats showed no toxicity when administered orally over a period of twelve weeks.
Preliminary observation in several men confirms the usefulness of the composition in increasing sexual desire and erectile function. For example, several men complained that age had caused them to lose sexual desire and the ability to have an erection. After taking the composition on a routine basis for eight weeks, these men reported enhanced sex drive and stability, sharpened sexual reflexes overall, improved energy and a sense of well-being. Other men found that there was more sexual desire, more energy and no side effects. From the foregoing, it is to be appreciated that the composition and method is effective in improving sexual desire and erectile function to increase sexual vitality and the male's sense of well-being and to improve sexual performance. The use of the composition may be substantially less expensive, less intrusive, and less toxic than some of the currently available treatments.
Although a particular embodiment of the invention has been described in detail for purposes of illustration, various modifications may be made without departing from the spirit and scope of the invention. Accordingly, the invention is not to be limited, except as by the appended claims.

Claims

CLAIMS1 CLAIM
1. A composition for improving sexual desire and erectile function comprising in the range of 40-65 mg Androstenedione, 20-45 mg 4-Androstenediol, 15 mg Zinc
Monomethionine aspartate, 80-125 mg Magnesium Aspartate, 20-45 mg B-6 (pyrodoxide HC1), 10-50 mg Lycopene, 60-125 mg Lecithin, 75-150 mg Serenoa Repens, and 75-200 mg Epimedium Sagittatum.
2. The composition of Claim 1, comprising about 50 mg Androstenedioine, about 25 mg 4-Androstenediol, 15 mg Zinc Monomethionine aspartate, about 100 mg Magnesium Aspartate, about 25 mg B-6 (pyrodoxide HC1), about 15 mg Lycopene, about 100 mg Lecithin, about 100 mg Serenoa Repens, and about 100 mg Epimedium Sagittatum.
3. The composition of Claim 1 , consisting essentially of about 50 mg Androstenedione, about 25 mg 4-Androstenediol, 15 mg Zinc Monomethionine aspartate, about 100 mg Magnesium Aspartate, about 25 mg B-6 (pyrodoxide HC1), about 15 mg Lycopene, about 100 mg Lecithin, about 100 mg Serenoa Repens, and about 100 mg Epimedium Sagittatum.
4. A composition comprising an effective amount to substantially improve sexual desire and erectile function of each of: Androstenedione, 4-Androstenediol,
Zinc Monomethionine aspartate, Magnesium Aspartate, B-6 (pyrodoxide HC1), Lycopene, Lecithin, Serenoa Repens, and Epimedium Sagittatum.
5. The composition of Claim 4, comprising in the range of 40-65 mg Androstenedione, 20-45 mg 4-Androstenediol, 15 mg Zinc Monomethionine aspartate, 80-125 mg Magnesium Aspartate, 20-45 mg B-6 (pyrodoxide HC1), 10-50 mg Lycopene, 60-125 mg Lecithin, 75-150 mg Serenoa Repens, and 75-200 mg Epimedium Sagittatum.
6. The composition of Claim 4, comprising about 50 mg Androstenedioine, about 25 mg 4-Androstenediol, 15 mg Zinc Monomethionine aspartate, about 100 mg Magnesium Aspartate, about 25 mg B-6 (pyrodoxide HO), about 15 mg Lycopene, about 100 mg Lecithin, about 100 mg Serenoa Repens, and about 100 mg Epimedium Sagittatum.
7. The composition of Claim 4, consisting essentially of about 50 mg Androstenedione, about 25 mg 4-Androstenediol, 15 mg Zinc Monomethionine aspartate, about 100 mg Magnesium Aspartate, about 25 mg B-6 (pyrodoxide HC1), about 15 mg Lycopene, about 100 mg Lecithin, about 100 mg Serenoa Repens, and about 100 mg Epimedium Sagittatum.
8. A method of improving sexual desire and erectile function comprising the steps of administering to a subject suffering from no or low sexual desire or erectile dysfunction, a composition comprising Androstenedione, 4-Androstenediol, Zinc Monomethionine aspartate, Magnesium Aspartate, B-6 (pyrodoxide HC1), Lycopene, Lecithin, Serenoa Repens, and Epimedium Sagittatum each in an effective amount for improving sexual desire and erectile function.
9. The method of Claim 8, wherein said composition comprises in the range of
40-65 mg Androstenedione, 20-45 mg 4-Androstenediol, 15 mg Zinc
Monomethionine aspartate, 80-125 mg Magnesium Aspartate, 20-45 mg B-6
(pyrodoxide HC1), 10-50 mg Lycopene, 60-125 mg Lecithin, 75-150 mg Serenoa
Repens, and 75-200 mg Epimedium Sagittatum.
10. The method of Claim 8, wherein said composition comprises about 50 mg Androstenedioine, about 25 mg 4-Androstenediol, 15 mg Zinc Monomethionine aspartate, about 100 mg Magnesium Aspartate, about 25 mg B-6 (pyrodoxide HCl), about 15 mg Lycopene, about 100 mg Lecithin, about 100 mg Serenoa Repens, and about 100 mg Epimedium Sagittatum.
11. The method of Claim 8, wherein said composition consists essentially of about 50 mg Androstenedione, about 25 mg 4-Androstenediol, 15 mg Zinc Monomethionine aspartate, about 100 mg Magnesium Aspartate, about 25 mg B-6 (pyrodoxide HCl), about 15 mg Lycopene, about 100 mg Lecithin, about 100 mg Serenoa Repens, and about 100 mg Epimedium Sagittatum.
12. The method of Claim 8, wherein said composition is administered orally.
13. The method of Claim 8, wherein said composition may be administered in
addition to VIAGRA®.
PCT/US2001/031447 2001-10-09 2001-10-09 Composition and method for improving sexual desire and erectile function WO2003030887A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2001/031447 WO2003030887A1 (en) 2001-10-09 2001-10-09 Composition and method for improving sexual desire and erectile function

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/031447 WO2003030887A1 (en) 2001-10-09 2001-10-09 Composition and method for improving sexual desire and erectile function

Publications (1)

Publication Number Publication Date
WO2003030887A1 true WO2003030887A1 (en) 2003-04-17

Family

ID=21742897

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/031447 WO2003030887A1 (en) 2001-10-09 2001-10-09 Composition and method for improving sexual desire and erectile function

Country Status (1)

Country Link
WO (1) WO2003030887A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008012988A1 (en) 2008-03-07 2009-09-10 S.W. Patentverwertungs Ltd. Composition and uses for influencing hair growth
ITLI20110007A1 (en) * 2011-09-10 2013-03-11 Lloyds Internat Credit Llc AN INNOVATIVE NATURAL COMPOSITION EFFECTIVE FOR THE CARE OF IMPOTENCE
KR101481709B1 (en) 2014-01-03 2015-02-02 인하대학교 산학협력단 Composition for preventing or treating erectile dysfunction comprising Sac-1004 compound

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE ADISALERTS [online] FIET ET AL.: "Differential changes in hormonal and sexual status in BPH patients treated by uncompetitive (permixon) or competitive (proscar) 5-alpha-reductase inhibitors", XP002907023, accession no. STN Database accession no. 2000:10709 *
JOURNAL OF UROLOGY, vol. 163, no. (SUPPL.), 1 April 2000 (2000-04-01), pages 308 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008012988A1 (en) 2008-03-07 2009-09-10 S.W. Patentverwertungs Ltd. Composition and uses for influencing hair growth
US11052059B2 (en) 2008-03-07 2021-07-06 Lucolas - M.D. Ltd Composition and uses for influencing hair growth
US11324711B2 (en) 2008-03-07 2022-05-10 S.W. Patentverwertungs Limited Composition and uses for influencing hair growth
US11974977B2 (en) 2008-03-07 2024-05-07 Lucolas—M.D. Ltd Composition and uses for influencing hair growth
ITLI20110007A1 (en) * 2011-09-10 2013-03-11 Lloyds Internat Credit Llc AN INNOVATIVE NATURAL COMPOSITION EFFECTIVE FOR THE CARE OF IMPOTENCE
KR101481709B1 (en) 2014-01-03 2015-02-02 인하대학교 산학협력단 Composition for preventing or treating erectile dysfunction comprising Sac-1004 compound

Similar Documents

Publication Publication Date Title
Lindström et al. Use of anabolic‐androgenic steroids among body builders—frequency and attitudes
US20080069903A1 (en) Electrical producing creams
CN108310311A (en) A kind of element culturing fixed folder strengthening yang and invigorating kidney Chinese medicine composition and preparation method
CN102716315B (en) Kidney yang tonifying health care medicinal liquor and preparation method thereof
CN102210844B (en) Chinese medicinal composition for treating chronic hepatitis and preparation method thereof
CN103520618A (en) Preparation method of okra plant viagra
CN108938989B (en) Fennel essence-coated bone-strengthening powder for treating osteoporosis
WO2003030887A1 (en) Composition and method for improving sexual desire and erectile function
WO2003047610A1 (en) Composition and method to increase female sexual desire and sexual satisfaction
CN108338980A (en) Purposes of the chlorogenic acid in the drug for preparing prevention inflammation of eye section
CN103610685A (en) Traditional Chinese medicinal composition for treating dysmenorrhea
WO2003053146A1 (en) Composition and method for improving sexual desire and overall sexual vitality
CN102114185B (en) Medicament for treating insulin resistance of type 2 diabetes
CN105343419A (en) Traditional Chinese medicinal pill for invigorating yang and tonifying kidney, and preparation method thereof
CN103610741A (en) Traditional Chinese medicinal composition for treating spermatorrhea
CN103599321A (en) Traditional Chinese medicine composition for treating osteoporosis
English Arginine and select phytonutrients enhance libido
CN106266895A (en) A kind of for Chinese medicine composition treating impotence and premature ejaculation and preparation method thereof
CN102266456A (en) Medicament for treating orthopedic disease and preparation thereof
Sapeika Drugs in obesity
Ozcan QUİNCKE DİSEASE İN EARTHQUAKE ZONE
CN1075883A (en) Promoting yang pill
ND Erectile dysfunction
CN106728581B (en) Application of pharmaceutical composition in preparation of medicine for treating asthenopia caused by long-term visual impairment
Tennant Jr (−)-α-Acetylmethadol for treatment of chronic pain patients who abuse opioids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ PH PL PT RO SD SE SG SI SK SL TJ TM TR TT TZ UG US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZW AM AZ BY KG KZ MD TJ TM AT BE CH CY DE DK ES FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC(EPO COMMUNICATION= FORM 1205A DATED:08.09.2004)

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP